title: HIV-exposed infants: rethinking care for a lifelong condition.
abstract: Each year over a million infants are born to HIV-infected mothers. With scale up of prevention of mother-to-child transmission (PMTCT) interventions, only 210 000 of the 1.3 million infants born to mothers with HIV/AIDS in 2012 became infected. Current programmatic efforts directed at infants born to HIV-infected mothers are primarily focused on decreasing their risk of infection, but an emphasis on maternal interventions has meant follow-up of exposed infants has been poor. Programs are struggling to retain this population in care until the end of exposure, typically at the cessation of breastfeeding, between 12 and 24 months of age. But HIV exposure is a life-long condition that continues to impact the health and well being of a child long after exposure has ended. A better understanding of the impact of HIV on exposed infants is needed and new programs and interventions must take into consideration the long-term health needs of this growing population. The introduction of lifelong treatment for all HIV-infected pregnant women is an opportunity to rethink how we provide services adapted for the long-term retention of mother-infant pairs.
authors.affiliation: aClinton Health Access Initiative, New York, New York bUNICEF New York, New York cIATT Secretariat New York, New York dBaylor College of Medicine Texas Childrens Hospital, Houston, Texas eUSAID, Washington DC fDivision of Global HIV/AIDS, Centers for Disease Control and Prevention Atlanta, Georgia gManagement Sciences for Health, Arlington, Virginia.
authors.forename: Nandita
authors.initials: N
authors.lastname: Sugandhi
authors.forename: Jessica
authors.initials: J
authors.lastname: Rodrigues
authors.forename: Maria
authors.initials: M
authors.lastname: Kim
authors.forename: Saeed
authors.initials: S
authors.lastname: Ahmed
authors.forename: Anouk
authors.initials: A
authors.lastname: Amzel
authors.forename: Mike
authors.initials: M
authors.lastname: Tolle
authors.forename: Eric J
authors.initials: EJ
authors.lastname: Dziuban
authors.forename: Scott E
authors.initials: SE
authors.lastname: Kellerman
authors.forename: Emilia
authors.initials: E
authors.lastname: Rivadeneira
mesh_terms: D019380:Anti-HIV Agents / Q000009:adverse effects / Q000627:therapeutic use; D044966:Anti-Retroviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002675:Child, Preschool; D005247:Feeding Behavior; D005260:Female; D015658:HIV Infections / Q000188:drug therapy / Q000453:epidemiology / Q000523:psychology / Q000635:transmission*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control*; D008134:Long-Term Care; D008297:Male; D008427:Maternal Health Services / Q000379:methods / Q000592:standards; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000517:prevention & control*; D011297:Prenatal Exposure Delayed Effects; D011314:Preventive Health Services
chemical_list: D019380:Anti-HIV Agents; D044966:Anti-Retroviral Agents